1. Clinical importance of serum secreted clusterin in predicting invasive breast cancer and treatment responses
- Author
-
Lei Chang, Qun Su, Bin Kong, Qing-Feng Chen, and Ying Zhao
- Subjects
0301 basic medicine ,Oncology ,Poor prognosis ,medicine.medical_specialty ,diagnosis ,clusterin ,medicine.medical_treatment ,Bioengineering ,Breast Neoplasms ,chemotherapy ,Applied Microbiology and Biotechnology ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Internal medicine ,Medicine ,Humans ,Clinical significance ,skin and connective tissue diseases ,Chemotherapy ,Clusterin ,biology ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,eye diseases ,030104 developmental biology ,Treatment Outcome ,030220 oncology & carcinogenesis ,biology.protein ,Female ,sense organs ,business ,TP248.13-248.65 ,Biotechnology ,Research Article ,Research Paper ,Invasive breast cancer - Abstract
Enhanced serum secreted clusterin (sCLU) protein was associated with progression, poor prognosis and chemotherapy sensitivity evaluation in malignant patients. However, the clinical significance of serum sCLU protein levels in patients with invasive breast cancer (IBC) is unknown. In this study, the serum sCLU protein in 2648 patients with IBC was detected. The diagnostic value and treatment responses of serum sCLU protein in patients with IBC were also performed. The results showed that the serum sCLU protein level was significantly higher in IBC patients compared to the healthy controls (P, Graphical abstract
- Published
- 2020